Medi-Cal no longer covers GLP-1s for weight loss as of Jan. 1.
Wegovy, Zepbound and Saxenda have been removed from the Medi-Cal Rx Contract Drugs List and are no longer eligible for coverage for weight loss or weight-loss indications.
The state will still consider prior authorization requests for Wegovy when prescribed for noncirrhotic metabolic dysfunction-associated steatohepatitis or cardiovascular disease, and for Zepbound when prescribed for obstructive sleep apnea.
Seven other GLP-1 drugs will remain on the formulary but only for type 2 diabetes: Ozempic, Rybelsus, Mounjaro, Victoza, Byetta, Bydureon and Trulicity.
Prior authorization requests for weight loss will be reviewed for medical necessity for beneficiaries younger than 21.
Sixteen state Medicaid programs, including California, covered GLP-1s when prescribed for the treatment of obesity as of October 1, 2025, according to KFF.
